Product Details
Product Name:
NCGC00135472 |
CAS No.:
862811-76-5 |
Purity:
99.54% |
Supply Ability:
10g |
Release date:
2024/11/17 |
Product Introduction
Bioactivity
名稱 | NCGC00135472 |
描述 | NCGC00135472 (DRV1 (GPR32) agonist C2A) is a human Resolvin DI receptor DRV1 agonist with pro-catabolic properties that activates the human soluble protein D1 receptor DRV1/GPR32 receptor in beta-blocker and cAMP assays with EC50s of 0.37 uM and 0.05 uM, respectively.NCGC00135472 induces in cells overexpressing recombinant DRV1 rapid impedance changes that stimulate phagocytosis of serum-treated zymoglycans. |
體外活性 | We implemented a high-throughput screening of small molecule libraries and identified chemotypes that activated recombinant DRV1, including NCGC00135472 (C2A). NCGC00135472 (100 nM to 10 mM) dose-dependently elicited rapid changes in impedance with CHO-DRV1.[1] |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 1.8 mg/mL (5.0 mM)
|
關(guān)鍵字 | NCGC00135472 |
相關(guān)庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2143952-36-5
$214.00 / 2mg
-
CAS:2058-46-0
$74.00 / 500mg
-
CAS:316173-57-6
$40.00 / 1mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |